| Primary |
| Convulsion |
43.4% |
| Epilepsy |
24.3% |
| Convulsion Prophylaxis |
5.2% |
| Grand Mal Convulsion |
4.7% |
| Ill-defined Disorder |
4.7% |
| Affective Disorder |
3.3% |
| Status Epilepticus |
3.2% |
| Drug Use For Unknown Indication |
1.6% |
| Petit Mal Epilepsy |
1.4% |
| Product Used For Unknown Indication |
1.1% |
| Multiple Sclerosis |
0.9% |
| Pain |
0.9% |
| Seizure |
0.9% |
| Tooth Repair |
0.9% |
| Blood Cholesterol Increased |
0.6% |
| Encephalitis |
0.6% |
| Toxicity To Various Agents |
0.6% |
| Allergy To Arthropod Sting |
0.5% |
| Bile Duct Obstruction |
0.5% |
| Cholangitis |
0.5% |
|
| Convulsion |
13.0% |
| Pharmaceutical Product Complaint |
13.0% |
| Drug Ineffective |
10.7% |
| Stevens-johnson Syndrome |
5.7% |
| Therapeutic Response Unexpected With Drug Substitution |
5.7% |
| Somnolence |
5.4% |
| Product Substitution Issue |
4.6% |
| Drug Toxicity |
4.2% |
| Vision Blurred |
4.2% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
3.8% |
| Toxic Epidermal Necrolysis |
3.8% |
| Toxicity To Various Agents |
3.8% |
| Treatment Noncompliance |
3.8% |
| Vomiting |
3.1% |
| Anticonvulsant Drug Level Increased |
2.7% |
| Purple Glove Syndrome |
2.7% |
| Tremor |
2.7% |
| Dizziness |
2.3% |
| Drug Level Increased |
2.3% |
| Nystagmus |
2.3% |
|
| Secondary |
| Convulsion |
30.5% |
| Epilepsy |
22.9% |
| Product Used For Unknown Indication |
13.3% |
| Drug Use For Unknown Indication |
4.3% |
| Grand Mal Convulsion |
3.3% |
| Anxiety |
2.7% |
| Convulsion Prophylaxis |
2.3% |
| Depression |
2.1% |
| Multiple Sclerosis |
2.1% |
| Petit Mal Epilepsy |
2.0% |
| Tooth Repair |
2.0% |
| Hypertension |
1.9% |
| Pain |
1.9% |
| Prophylaxis |
1.6% |
| Blood Cholesterol Increased |
1.3% |
| Ill-defined Disorder |
1.3% |
| Atrial Fibrillation |
1.1% |
| Intracranial Aneurysm |
1.1% |
| Partial Seizures |
1.1% |
| Prophylaxis Against Gastrointestinal Ulcer |
1.1% |
|
| Convulsion |
12.8% |
| Stevens-johnson Syndrome |
8.7% |
| Drug Ineffective |
8.1% |
| Tremor |
6.7% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
6.0% |
| Status Epilepticus |
6.0% |
| Rash |
5.4% |
| Myocardial Infarction |
4.7% |
| Weight Increased |
4.7% |
| White Blood Cell Count Decreased |
4.7% |
| Somnolence |
4.0% |
| Toxic Epidermal Necrolysis |
4.0% |
| Drug Interaction |
3.4% |
| Epilepsy |
3.4% |
| Grand Mal Convulsion |
3.4% |
| Rash Maculo-papular |
3.4% |
| Fall |
2.7% |
| Thrombocytopenia |
2.7% |
| Vertigo |
2.7% |
| Vomiting |
2.7% |
|
| Concomitant |
| Product Used For Unknown Indication |
30.0% |
| Drug Use For Unknown Indication |
18.2% |
| Epilepsy |
13.7% |
| Prophylaxis |
9.3% |
| Convulsion |
4.1% |
| Hiv Infection |
4.1% |
| Rheumatoid Arthritis |
3.1% |
| Osteoporosis |
2.8% |
| Pain |
2.0% |
| Hypertension |
1.8% |
| Partial Seizures |
1.3% |
| Pre-eclampsia |
1.3% |
| Depression |
1.2% |
| Upper Respiratory Tract Inflammation |
1.2% |
| Constipation |
1.2% |
| Nausea |
1.2% |
| Blood Pressure |
0.9% |
| Partial Seizures With Secondary Generalisation |
0.9% |
| Crohn's Disease |
0.8% |
| Diarrhoea |
0.8% |
|
| Epilepsy |
10.1% |
| Convulsion |
8.0% |
| Vomiting |
8.0% |
| Myocardial Infarction |
7.2% |
| Pyrexia |
5.8% |
| Toxic Epidermal Necrolysis |
5.8% |
| Granulocytopenia |
5.1% |
| Renal Failure Acute |
5.1% |
| Respiratory Arrest |
5.1% |
| Type 2 Diabetes Mellitus |
5.1% |
| Respiratory Failure |
4.3% |
| Weight Decreased |
4.3% |
| Injection Site Cellulitis |
3.6% |
| Oedema Mouth |
3.6% |
| Syncope |
3.6% |
| Weight Increased |
3.6% |
| Anticonvulsant Drug Level Increased |
2.9% |
| Brain Oedema |
2.9% |
| Grand Mal Convulsion |
2.9% |
| Headache |
2.9% |
|
| Interacting |
| Epilepsy |
30.2% |
| Product Used For Unknown Indication |
23.0% |
| Upper Respiratory Tract Inflammation |
12.7% |
| Grand Mal Convulsion |
6.3% |
| Reflux Oesophagitis |
6.3% |
| Convulsion |
5.6% |
| Colorectal Cancer Metastatic |
2.4% |
| Drug Use For Unknown Indication |
2.4% |
| Behcet's Syndrome |
1.6% |
| Candidiasis |
1.6% |
| Atrial Fibrillation |
0.8% |
| Headache |
0.8% |
| Hyperchlorhydria |
0.8% |
| Hypersensitivity |
0.8% |
| Infection |
0.8% |
| Malignant Melanoma |
0.8% |
| Nervous System Disorder |
0.8% |
| Oedema Peripheral |
0.8% |
| Sinusitis |
0.8% |
| Urinary Tract Infection |
0.8% |
|
| Drug Interaction |
21.2% |
| Peripheral Coldness |
18.2% |
| Toxicity To Various Agents |
12.1% |
| Aphasia |
9.1% |
| Vertigo |
6.1% |
| Adverse Event |
3.0% |
| Convulsion |
3.0% |
| Dysarthria |
3.0% |
| Gait Disturbance |
3.0% |
| Headache |
3.0% |
| Loss Of Consciousness |
3.0% |
| Rash Pruritic |
3.0% |
| Respiratory Disorder |
3.0% |
| Rotator Cuff Syndrome |
3.0% |
| Toxic Skin Eruption |
3.0% |
| Vomiting |
3.0% |
|
